Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Novo Nordisk Plan NASH Collaboration

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 06:26am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO, NVO) on Friday said they will collaborate on a clinical trial combining compounds from their pipelines in nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.

The companies said the trial will be a proof-of-concept study combining Novo's semaglutide and Gilead's cilofexor and firsocostat for the treatment of patients with NASH.

Gilead, a Foster City, Calif., biopharmaceutical company, and Danish pharmaceutical company Novo said they also may collaborate on preclinical research to advance understanding of the disease, which often affects people with diabetes and metabolic syndrome.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 0.88% 66.36 Delayed Quote.6.09%
NOVO NORDISK AS 0.10% 313.3 Delayed Quote.5.17%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
05/15GILEAD SCIENCES : Kite to Present New Data From Leading Cell Therapy Portfolio a..
BU
05/15GILEAD SCIENCES : To Donate HIV Prevention Pill Truvada To 200,000 People
AQ
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/14GILEAD SCIENCES : Statement On Inaccurate Reporting On Truvada®
PU
05/11GILEAD SCIENCES : Goldfinch to team up against kidney disease
AQ
05/10GILEAD SCIENCES : HHS chief announce donation of HIV prevention drug Truvada
AQ
05/09GILEAD SCIENCES : Drugmaker will donate meds for US push to end HIV epidemic
AQ
05/09GILEAD SCIENCES : to Provide Free Truvada for PrEP® to Support U.S. Initiative t..
BU
05/09GILEAD SCIENCES INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
05/09PFIZER : New Biktarvy spot puts Gilead in top TV-spending ranks, right behind Ab..
AQ
More news
Financials ($)
Sales 2019 22 041 M
EBIT 2019 11 424 M
Net income 2019 6 929 M
Debt 2019 8 472 M
Yield 2019 3,81%
P/E ratio 2019 12,27
P/E ratio 2020 12,03
EV / Sales 2019 4,21x
EV / Sales 2020 3,78x
Capitalization 84 380 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 81,1 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.09%84 380
VERTEX PHARMACEUTICALS1.82%43 215
REGENERON PHARMACEUTICALS-18.36%32 850
GENMAB7.78%10 630
SAREPTA THERAPEUTICS INC11.49%9 022
BEIGENE LTD--.--%8 093